Dicerna Pharmaceuticals, Inc.
Employer · Massachusetts, United States
- Employer address
- Massachusetts, United States
- Applications on record
- 75
- FY2025 applications
- 9
- FY2026 to 30 June
- 0
- Programmes
- LCA · PERM
- Certified (last three years)
- 100.0%
- Median offered wage
- $130,000
- Most common occupation
- Biological Scientists, All Other
- H-1B dependent (as declared)
- No
VE<USADICERNA<PHARMACEUTICALS<INC<<<<<<<<<<< MA756<FY20102<FY2026Q32<<<<<<<<<<<<<<<<<<<<4
Applications year by year
Dicerna Pharmaceuticals, Inc. appears in 75 applications filed with the U.S. Department of Labor between fiscal 2010 and fiscal 2026 (to 30 June). In fiscal 2025 it filed 9.
Applications by fiscal year — Dicerna Pharmaceuticals, Inc.
Data table
| FY2010 | 1 |
| FY2011 | 4 |
| FY2012 | 2 |
| FY2013 | 0 |
| FY2014 | 0 |
| FY2015 | 6 |
| FY2016 | 3 |
| FY2017 | 3 |
| FY2018 | 1 |
| FY2019 | 8 |
| FY2020 | 4 |
| FY2021 | 7 |
| FY2022 | 8 |
| FY2023 | 6 |
| FY2024 | 13 |
| FY2025 | 9 |
| FY2026* | 0 |
| Fiscal year | LCA | PERM |
|---|---|---|
| FY2026* | 0 | 0 |
| FY2025 | 8 | 1 |
| FY2024 | 11 | 2 |
| FY2023 | 6 | 0 |
| FY2022 | 8 | 0 |
| FY2021 | 7 | 0 |
| FY2020 | 4 | 0 |
| FY2019 | 7 | 1 |
| FY2018 | 1 | 0 |
| FY2017 | 3 | 0 |
| FY2016 | 3 | 0 |
| FY2015 | 6 | 0 |
| FY2014 | 0 | 0 |
| FY2013 | 0 | 0 |
| FY2012 | 2 | 0 |
| FY2011 | 4 | 0 |
| FY2010 | 1 | 0 |
Where the jobs are
Worksite of each application as filed (first worksite where several are listed).
Dicerna Pharmaceuticals, Inc.: applications by worksite state
Data table
| State | Applications |
|---|---|
| MA | 74 |
| CO | 1 |
- Lexington, MA47
- Cambridge, MA20
- Watertown, MA7
- Boulder, CO1
What they hire for and pay
Occupations, job titles and offered wages as stated on the applications.
- Research Associate11
- Scientist I8
- Associate Scientist I6
- Research Associate, Rnai Discovery4
- Senior Research Associate, Rnai Discovery3
- Senior Research Associate3
- Senior Scientist I3
- Formulation Scientist2
Offered annual wage, FY2024–FY2026, 10th to 90th percentile
Median $130,000; middle half $106,217 to $147,500 · median prevailing wage $114,421 (marker) · 19 applications.
- Level I2
- Level II5
- Level III6
- Level IV6
H-1B petitions decided by USCIS
Approvals and denials of Form I-129 petitions, by USCIS fiscal year. Linked by employer name, state and the last four digits of the tax ID.
Approved H-1B petitions (initial + continuing)
Data table
| FY2010 | 1 |
| FY2011 | 4 |
| FY2012 | 1 |
| FY2013 | 3 |
| FY2016 | 2 |
| FY2018 | 1 |
| FY2019 | 3 |
| FY2020 | 5 |
| FY2021 | 7 |
| FY2022 | 7 |
| FY2023 | 0 |
| Fiscal year | Initial approvals | Initial denials | Continuing approvals | Continuing denials |
|---|---|---|---|---|
| FY2023 | 0 | 0 | 0 | 1 |
| FY2022 | 4 | 0 | 3 | 0 |
| FY2021 | 0 | 0 | 7 | 0 |
| FY2020 | 3 | 0 | 2 | 0 |
| FY2019 | 1 | 0 | 2 | 0 |
| FY2018 | 0 | 0 | 1 | 0 |
| FY2016 | 0 | 0 | 2 | 0 |
| FY2013 | 1 | 0 | 2 | 0 |
| FY2012 | 1 | 0 | 0 | 0 |
| FY2011 | 3 | 0 | 1 | 0 |
| FY2010 | 1 | 0 | 0 | 0 |
Law firms on the filings
Firms named as the employer's representative (firm names only).
Among employers in Massachusetts
Dicerna Pharmaceuticals, Inc. has 75 work visa applications on record (FY2010–FY2026), ranking #602 of 6,297 sponsoring employers in Massachusetts and #15,247 of 168,030 in the United States; that is 0.02% of the applications filed by employers based in Massachusetts.
- Rank in Massachusetts
- 602 of 6,297
- Rank in the United States
- 15,247 of 168,030
- Share of Massachusetts's applications
- 0.02%
- Employers in the same industry group (NAICS 325) in Massachusetts
- 142
- Virtusa Corporation13,005
- Randstad Technologies, LLC11,730
- Fidelity Technology Group, LLC11,656
- Patni Americas Inc.10,160
- NTT Data, Inc.9,000
- The Boston Consulting Group, Inc.8,475
- The Mathworks, Inc.8,037
- Emc Corporation6,787
- Avco Consulting Inc6,325
- Harvard University6,206
Official data, not advice. Visa Atlas publishes figures from government registers and statistics. It does not assess eligibility or give immigration advice; for advice, consult a regulated adviser. Read more